STUDY OF THE HYPOGLYCEMIC AND CARDIOPROTECTIVE EFFECT OF EMPAGLIFLOZIN IN THERAPY OF PATIENTS WITH TYPE 2 DIABETES MELLITUS
Keywords:
type 2 diabetes mellitus, atherosclerotic cardiovascular disease, sodium glucose cotransporter typeAbstract
The aim of our study was to study the hypoglycemic and cardioprotective effect of empagliflozin in patients with type 2 diabetes mellitus cardiovascular diseases
References
Algorithms of specialized medical care for
patients with diabetes mellitus. Ed. I.I. Dedova,
M.V. Shestakova, A.Yu. Mayorova. 10th _ issue
. (add.). M .; 2021. [Standards of specialized
diabetes care. Eds.: Dedov II, Shestakova MV,
Mayorov A.Yu. _ 10th edition (revised). M .;
(in Russian). DOI: 10.14341/DM12802.
American Diabetes Association Professional
Practice Committee, American Diabetes
Association Professional Practice Committee,
Draznin B. et al. 9. Pharmacologic Approaches
to Glycemic Treatment: Standards of Medical
Care in Diabetes-2022. diabetes care . 2022;45(
Suppl 1 ): S 125– S 143. DOI : 10.2337/ dc 22-
S 009.
I. Z. Bondarenko and M. G. Bubnova, Russ.
What's new in the treatment of a patient with
diabetes mellitus and cardiovascular diseases:
a view of cardiologists. CardioSomatics . 2018;
(2): 24–30. DOI: 10.26442/2221-
_2018.2.24-30
Sergienko I. V., Ansheles A. A., Khalimov Yu.
Sh., Shestakova M. V., Boitsov S. A. K21
CARDIOLOGICAL ASPECTS OF TYPE 2
DIABETES MELLITUS. - Moscow: Pero
Publishing House, 2018 - 68 p.
Drunk O.P. Multifactorial management of type 2
diabetes in patients with very high
cardiovascular risk // Endocrinology: news,
opinions, training. 2021. V. 10, No. 3. C. 75–81.
DOI: https://doi. org /10.33029/2304-9529-
-10-3-75-81
Cherney DZ, Perkins BA, Soleymanlou N. et al.
Renal hemodynamic
effect of sodium-glucose cotransporte r 2
inhibition in patients with type 1
diabetes mellitus // Circulation. 2014. Vol. 129.
P. 587–597
Inzucchi SE, Zinman B., Fitchett D. et al. How
does empagliflozin reduce cardiovascular
mortality? Insights from a mediation analysis of
theEMPA -REG OUTCOME trial // Diabetes Care.
Vol . 41. P
IDF Diabetes Atlas. 9th edition. 2019.
(Electronic resource.) URL:
https://diabetesatlas.org/atlas/ninth-edition/
(access date: 01/21/2022).
Inzucchi SE, Khunti K., Fitchett DH, et al. 19-
LB: consistent cardiovascular (CV) benefits
from empagliflozin across the spectrum of CV
risk factor control: post hoc analysis from
EMPA-REG OUTCOME. diabetes. 2019; 68(1).
Zinman B., Wanner C., Lachin JM, et al. Empagli
_ ozin , cardiovascular outcomes, and mortality
in type 2 diabetes. N Engl J Med . 2015;
:2117–28.
Hammoudi N, Jeong D, Singh R, Farhat A,
Komajda M, Mayoux E, Hajjar R, Lebeche D .
Empagliflozin improves left ventricular diastolic
dysfunction in ageetic model of type 2 diabetes.
Cardiovascular Drugs and Therapy.
;31(3):233-246.]
Habibi J, Aroor AR, Sowers JR, Jia G, Hayden
MR, Garro M, Barron B, Mayoux E, Rector RS,
Whaley-Connell A, DeMarco VG. Sodium
glucose transporter 2 (SGLT2) inhibition with
empagliflozin improves cardiac diastolic
function in a female rodent model of diabetes.
Cardiovascular Diabetology . 2017;16(1):9
Rawshani A., Rawshani A., Franzén S., et al.
Mortality and cardiovascular disease in type 1
and type 2 diabetes. N Engl J Med . 2017;
:1407–18.
Empagliflozin as a new management strategy
for patients with type 2 diabetes March 2017
Diabetes Mellitus 19 (6):494
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
